SAN DIEGO, CA, March 4, 2024 – Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced that Fierce Medtech has named it as one of 2023’s “Fierce 15” medical technology companies. The annual special report features the most innovative private medtech companies in the industry.
“This award is a testament to the hard work and determination of the entire Element team,” said Element CEO and Co-founder Molly He. “In an industry long dominated by legacy players, we have consistently broken down barriers through innovation, empowering scientists to accelerate their progress.”
Element was chosen for the remarkable strides they are making to democratize sequencing and biological tools globally, bringing more cost-effective, accessible tools to labs across the world. This year, Element is setting its sights beyond DNA, and in January the company shared a roadmap for new products launching in 2024, including AVITI24, the first instrument that can simultaneously analyze multiple biological signals (DNA, RNA, proteins, phosphorylated proteins, and cell morphology).
“Every year we celebrate a few of the most innovative toolmakers, whether they’re focused on helping clinicians reach, diagnose and treat the sick, or assisting the researchers chasing the next scientific and medical breakthroughs,” said Conor Hale, senior editor of Fierce Medtech. “These companies exemplify the ability of the medtech industry to turn cutting-edge ideas into meaningful outcomes and make them accessible on a large scale.”
About Fierce Medtech
Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. Top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.
About Element Biosciences, Inc.
Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing and other omics technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn and Facebook.
Media Contact
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com